Mankind Pharma · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Management admitted disappointment with organic domestic growth (6% vs historical 1.3x IPM outperformance). Sales force restructuring took longer than expected (12+ months vs 6-9 months targeted) as new representatives require time to build doctor relationships in tier 2-4 markets.
EBITDA margin declined 80bps YoY to 25% in Q2, with management guiding to lower end of 25-26% for full year. R&D increased 100bps, employee costs up 130bps, and GST-related stockist compensation impacted gross margins.
Analyst raised concern about chronic outperformance gap narrowing vs IPM over past several quarters. Management attributed this to price hike discipline (3.9% vs IPM 4.2%) and transformation disruptions, but acknowledged historical advantage may not sustain.
OTC revenue declined 3% YoY due to GST disruption and uneven monsoons, with primary sales impacted more than secondary sales (Manforce +14%, Gopex +36%). Recovery in H2 is expected but uncertain.
